Cellebrite DI (NASDAQ:CLBT) Reaches New 12-Month Low – Here’s What Happened

Cellebrite DI Ltd. (NASDAQ:CLBT) reached a new 52-week low on Monday . The stock traded as low as $12.34 and last traded at $12.3090, with a volume of 729522 shares traded. The stock had previously closed at $13.16.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Wall Street Zen downgraded Cellebrite DI from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. JPMorgan Chase & Co. boosted their price objective on shares of Cellebrite DI from $23.00 to $24.00 and gave the company an “overweight” rating in a research report on Thursday, November 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Cellebrite DI in a report on Monday, December 29th. Bank of America lifted their target price on shares of Cellebrite DI from $24.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Finally, Lake Street Capital boosted their price target on shares of Cellebrite DI from $22.00 to $23.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Cellebrite DI currently has a consensus rating of “Moderate Buy” and an average price target of $22.50.

Cellebrite DI Stock Performance

The stock’s 50-day moving average price is $16.59 and its two-hundred day moving average price is $17.03. The stock has a market capitalization of $2.85 billion, a PE ratio of 38.37, a P/E/G ratio of 2.02 and a beta of 1.28.

Cellebrite DI (NASDAQ:CLBT) last issued its quarterly earnings results on Wednesday, February 11th. The company reported $0.14 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.14. The company had revenue of $128.82 million during the quarter, compared to analysts’ expectations of $126.07 million. Cellebrite DI had a net margin of 16.47% and a return on equity of 20.43%. Cellebrite DI’s revenue was up 28.8% on a year-over-year basis. During the same period last year, the company posted $0.10 EPS. On average, analysts predict that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

Institutional Trading of Cellebrite DI

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Cooper Creek Partners Management LLC purchased a new position in Cellebrite DI during the third quarter valued at $55,999,000. Granahan Investment Management LLC increased its holdings in shares of Cellebrite DI by 1,108.5% during the third quarter. Granahan Investment Management LLC now owns 2,629,299 shares of the company’s stock valued at $48,721,000 after acquiring an additional 2,411,726 shares in the last quarter. Capital International Investors purchased a new position in shares of Cellebrite DI in the 4th quarter worth about $41,073,000. Invesco Ltd. raised its position in shares of Cellebrite DI by 58.6% in the 3rd quarter. Invesco Ltd. now owns 5,560,196 shares of the company’s stock worth $103,030,000 after purchasing an additional 2,054,644 shares during the last quarter. Finally, Pertento Partners LLP boosted its stake in Cellebrite DI by 57.8% in the 3rd quarter. Pertento Partners LLP now owns 4,648,215 shares of the company’s stock worth $86,131,000 after purchasing an additional 1,702,574 shares in the last quarter. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.